BRNS Barinthus Biotherapeutics plc
USHealthcareAs of 2026-07-10 16:00
Why BRNS matters now
Barinthus Biotherapeutics plc (BRNS) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.64 with -0.02% on the session and $26.1M in market capitalization; recent performance reads 1-month -3.13% and YTD -5.43%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.5M, and EPS of $-0.14. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -134.7%.
The latest indexable market news headline is "Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders?" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $3.00; recent insider activity includes Swirsky Douglas J filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.41
P/S
0.00
EV/EBITDA
0.61
DCF Value
$1.48
FCF Yield
-134.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-63.9%
ROA
-56.7%
ROIC
-68.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.5M | $-0.14 |
| Q4 2025 | $0.00 | $-11.1M | $-0.27 |
| FY 2025 | $0.00 | $-66.6M | $-1.64 |
| Q3 2025 | $0.00 | $-14.6M | $-0.36 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$3.00
Target (Median)
$3.00
Target Range
$3.00 - $3.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
GB
Exchange
—
Beta
-0.40
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.